About: Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm
Creator	Wang, Haichao Es, Alberto Gonzalez-Rubio, Jesus Gonzalez-Rubio, J Jimenez-Diaz, A Jimenez-Diaz, Lydia Lopez-Najera, Ana Lopez-Najera, Elena Lopez-Najera, Lopez-Najera E Mikkelsen, Jens Najera, Alberto Najera, Navarro-Lopez, Carmen Navarro-Lopez, Juan Navarro-Lopez, C Navarro-Lopez, L Navarro@uclm, Juan Salminen, Outi Simard, Alain
Source	Medline; PMC
abstract	SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.01359
bibo:pmid	32595653
has license	cc-by
sha1sum (hex)	f96b375b7233bb26475467ebd088c2bdd3e1e6f2
schema:url	https://doi.org/10.3389/fimmu.2020.01359
resource representing a document's title	Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm
has PubMed Central identifier	PMC7300218
has PubMed identifier	32595653
schema:publication	Front Immunol
resource representing a document's body	covid:f96b375b7233bb26475467ebd088c2bdd3e1e6f2#body_text
is schema:about of	named entity 'NEW' named entity 'TO INHIBIT' named entity 'TREATMENTS' named entity 'NOVEL' named entity 'SEVERE' named entity 'GREAT' named entity 'INFLAMMATION' named entity 'USED' named entity 'China' named entity 'Nicotine' named entity 'agonist' named entity 'smokers' named entity 'coronavirus' named entity 'signal transduction pathway' named entity 'inflammation' named entity 'nicotinic acetylcholine receptors' named entity 'cytokine release syndrome' named entity 'cytokine storm' named entity 'epidemiological' named entity 'Cytokine Release Syndrome' named entity 'nicotine' named entity 'Tocilizumab' named entity 'nicotine' named entity 'antiinflammatory' named entity 'TNFa' named entity 'ulcerative Colitis' named entity 'MERS-CoV' named entity 'agonists' named entity 'clinical trials' named entity 'nicotinic' named entity 'hyperinflammation' named entity 'sublingual tablets' named entity 'Italy' named entity 'systemic inflammation' named entity 'short term' named entity 'Nicotine' named entity 'lung' named entity 'inflammatory responses' named entity 'pneumonia' named entity 'Tocilizumab' named entity 'cytokine release syndrome' named entity 'short term' named entity 'macrophages' named entity 'nicotine' named entity 'inflammatory response' named entity 'electronic cigarettes' named entity 'SARS-CoV-2 outbreak' named entity 'nicotine' named entity 'Wuhan' named entity 'SARS-CoV-2' named entity 'cytokine storm' named entity 'inflammatory diseases' named entity 'SARS-CoV-2' named entity 'China' named entity 'cytokine storm' named entity 'nicotine' named entity 'murine' named entity 'acute lung injury' named entity 'IL-6' named entity 'SARS-CoV-2' named entity 'cytokine storm' named entity 'secretion' named entity 'cytokines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software